HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $64

Benzinga Newsdesk www.benzinga.com Positive 82.8%

Neg 0% Neu 0% Pos 82.8%

HC Wainwright & Co. analyst Joseph Pantginis maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $42 to $64.